Table 4.
Prevalence of anti-neutrophil cytoplasmic antibodies in biliary atresia patients and non-biliary atresia controls n (%)
| Variable | BA, n = 124 | Other liver diseases1, n = 92 | Healthy, n = 48 |
| ANCA, by IIF | 36 (29.0)a | 23 (25.0) | 2 (4.2) |
| c-ANCA | 10 (8.1) | 1 (1.1) | 0 (0) |
| p-ANCA | 25 (20.2) | 21 (22.8) | 2 (4.2) |
| a-ANCA | 1 (0.8) | 1 (1.1) | 0 (0) |
| Specific ANCA, by ELISA | |||
| Anti-MPO | 11 (8.9) | 6 (6.5) | 2 (4.2) |
| Anti-PR3 | 19 (15.3) | 13 (14.2) | 0 (0) |
| Anti-MPO and/or anti-PR3 | 23 (18.0)a | 13 (14.2) | 2 (4.2) |
| ANCAs | 47 (37.9)a | 31 (33.7) | 3 (6.3) |
1
Choledochal cysts, transient cholestasis of unknown origin, and neonatal intrahepatic cholestasis caused by citrin deficiency were included as disease controls.
a
P < 0.05 vs healthy controls. Anti-MPO and/or anti-PR3: Any positivity of specific ANCAs; ANCAs: Any positivity of ANCAs by IIF or specific ANCA by ELISA. ANCA: Anti-neutrophil cytoplasmic antibody; BA: Biliary atresia; ELISA: Enzyme linked immunosorbent assay; IIF: Indirect immunofluorescence.